05-06-2026 23:55 via drugs.com

~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2

FRIDAY, June 5, 2026-- About 16 percent of COVID-19 cases develop postacute sequelae of severe acute respiratory syndrome coronavirus-2 infection (PASC), according to a study published online May 27 in JAMA Network Open.Jiazi Tian, from...

Prayer at Primary Care Appointments Tied to Reductions in Pain, Anxiety

ASCO: Tile-Based Radiation Beneficial for Newly Resectable Brain Mets

ASCO: Apalutamide + ADT Beneficial in High-Risk Localized Prostate Cancer

Wearable Ultrasound Patch Provides Continuous Fetal Monitoring

Cardiometabolic Genetics Linked to Cognitive-Related Outcomes

Dose Reduction of Biologics Effective, Safe for Psoriasis

High Prevalence of Clinical Obesity Seen Even With Normal BMI

FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection

ASCO: Lower Incidence of Breast Cancer Seen With GLP-1 Receptor Agonist Exposure

ASCO: First-Line Sunvozertinib Beats Chemo for Advanced NSCLC

Patients From Most Rural Counties Have Worse Epilepsy Outcomes

2024 Saw Parkinson Disease Death Rate of 72 Per 100,000 Adults Aged 65 and Older

Resistance Training Tied to Lower Risk for Death Across Causes

Gut Microbial, Metabolomic Alterations Persist After Adenoma Resection

Desktop versie

~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2

Pharmaceutical Industry news